Portal de Periódicos da CAPES

QUANTITATIVE IMMUNOHISTOCHEMICAL ANALYSIS OF INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-3 IN HUMAN PROSTATIC ADENOCARCINOMA: A PROGNOSTIC STUDY

1998; Lippincott Williams & Wilkins; Volume: 159; Issue: 6 Linguagem: Inglês

10.1016/s0022-5347(01)63309-3

1527-3792

ORI Z. HAMPEL, Michael W. Kattan, Guang Yang, Sigmund J. Haidacher, GEORGES Y. SALEH, Timothy C. Thompson, Thomas M. Wheeler, Marco Marcelli,

Prostate Cancer Diagnosis and Treatment

No AccessJournal of UrologyInvestigative Urology1 Jun 1998QUANTITATIVE IMMUNOHISTOCHEMICAL ANALYSIS OF INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-3 IN HUMAN PROSTATIC ADENOCARCINOMA: A PROGNOSTIC STUDY ORI Z. HAMPEL, MICHAEL W. KATTAN, GUANG YANG, S.JOE HAIDACHER, GEORGES Y. SALEH, TIMOTHY C. THOMPSON, THOMAS M. WHEELER, and MARCO MARCELLI ORI Z. HAMPELORI Z. HAMPEL , MICHAEL W. KATTANMICHAEL W. KATTAN , GUANG YANGGUANG YANG , S.JOE HAIDACHERS.JOE HAIDACHER , GEORGES Y. SALEHGEORGES Y. SALEH , TIMOTHY C. THOMPSONTIMOTHY C. THOMPSON , THOMAS M. WHEELERTHOMAS M. WHEELER , and MARCO MARCELLIMARCO MARCELLI View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)63309-3AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We sought to characterize and quantitate the expression of IGFBP-3 in adenocarcinoma of the prostate and to test whether it correlated with tumor differentiation determined by Gleason grade. We also investigated the potential of using IGFBP-3 as a prognostic indicator of clinically localized prostate cancer. Materials and Methods: Initially we evaluated the expression of IGFBP-3 in six normal and twenty neoplastic prostates using standard immunohistochemical techniques (study 1). We then obtained radical prostatectomy specimens from twenty-four patients with a preoperative diagnosis of clinically localized prostate adenocarcinoma and five year follow up information, and nine normal prostates from organ donors or from patients undergoing cystoprostatectomy (study 2). All specimens were immunostained with a polyclonal anti-human IGFBP-3 antibody. A single pathologist reviewed all sections and assigned a Gleason grade to each cancer focus. Using computer-assisted video image analysis, we quantified the intensity of IGFBP-3 immunostaining of each cancer focus and of normal controls. Results: Normal prostatic epithelium showed intense cytoplasmic IGFBP-3 staining. The stromal compartment showed less intense staining, although there were occasional areas with strong immunoreactivity. The cellular distribution of IGFBP-3 staining in prostatic adenocarcinoma was comparable to normal tissue; however, the intensity of detectable staining in neoplastic epithelial cells was significantly decreased. Two foci of prostatic intraepithelial neoplasia (PIN) demonstrated IGFBP-3 immunoreactivity decreased in comparison to normal epithelium, but greater than prostatic adenocarcinoma. Histologically normal epithelium surrounding cancer foci also showed decreased immunostaining for IGFBP-3 compared with normal prostate. The marked decrease in immunostaining intensity of IGFBP-3 in prostate adenocarcinoma was not associated with Gleason grade or with clinical outcome. Conclusion: Malignant transformation of prostatic epithelium was associated with a significant decrease in the amount of immunoreactive IGFBP-3 (p <0.0001); however, this parameter did not correlate with Gleason grade of the tumor or with patient outcome. The decrease in immunostaining intensity of IGFBP-3 in all Gleason grades and in PIN suggests that lower expression of IGFBP-3 is an early event in prostatic carcinogenesis. The finding that decreased IGFBP-3 immunostaining did not correlate with clinical outcome suggests that this parameter is not a therapy-guiding prognostic indicator for clinically localized prostate cancer. References 1 : Insulin-like growth factor binding proteins: structural and molecular relationships. Growth Factors1991; 5: 19. Crossref, Medline, Google Scholar 2 : Editorial: insulin-like growth factors (IGF)-binding proteins in serum-Do they have additional roles beside modulating the endocrine IGF actions? J. Clin. Endocrinol. Metab.1996; 81: 3821. Crossref, Google Scholar 3 : Synthesis and characterization of Insulin-like growth factor binding protein (IGFBP)-7. J. Biol. Chem.1996; 271: 30322. Crossref, Medline, Google Scholar 4 Kim, H., Nagalla, S., Oh, Y., Wilson, E., Roberts, C. and Rosenfeld, R.: Synthesis and characterization of connective tissue growth factor (CTGF) as insulin-like growth factor in binding protein (IGFBP)-9. Endocrine Society Annual Meeting, Minneapolis, MN, pp. 352, 1997. Google Scholar 5 : Proteolysis of IGFBP-3 may be a common regulatory mechanism of IGF action in vivo. Growth Reg.1993; 3: 91. Medline, Google Scholar 6 : Insulin-like growth factor-I (IGF-I) and its binding protein IGFBP-4 in human prostatic hyperplastic tissue: gene expression and its cellular localization. J. Clin. Endocrinol. Metab.1994; 78: 778. Medline, Google Scholar 7 : Insulin-like growth factor axis abnormalities in prostatic stromal cells from patients with benign prostatic hyperplasia. J. Clin. Endocrinol. Metab.1994; 79: 1410. Medline, Google Scholar 8 : Protein and messenger ribonucleic acid (mRNA) for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium. J. Clin. Endocrinol. Metab.1996; 81: 3774. Medline, Google Scholar 9 : Secretion of insulin-like growth factors and their binding proteins by human normal and hyperplastic prostatic cells in primary culture. J. Clin. Endocrinol. Metab.1996; 81: 612. Medline, Google Scholar 10 : Insulin-like growth factor-binding proteins (IGFBP)-4, −5, −6 in the benign and malignant human prostate: IGFBP-5 messenger ribonucleic acid localization differs from IGFBP-5 protein localization. J. Clin. Endocrinol. Metab.1996; 81: 3783. Medline, Google Scholar 11 : Autocrine regulation of cell proliferation by the insulin-like growth factor (IGF) and IGF binding protein-3 protease system in a human prostate carcinoma cell line (PC-3). Endocrinology1995; 136: 5485. Crossref, Medline, Google Scholar 12 : Proliferation of cultured human prostate cancer cells is inhibited by insulin-like growth factor (IGF) binding protein-1: evidence for and IGF-II autocrine growth loop. J. Clin. Endocrinol. Letab.1995; 80: 3476. Crossref, Medline, Google Scholar 13 : Insulin-like growth factor-I receptors in human hyperplastic prostate tissue: characterization, tissue localization, and their modulation by chronic treatment with a gonadotropin-releasing hormone analog. J. Clin. Endocrinol. Metab.1991; 72: 740. Crossref, Medline, Google Scholar 14 : Growth factors in the human prostate. J. Steroid Biochem. Mol. Biol.1991; 40: 199. Crossref, Medline, Google Scholar 15 : Insulin-like like growth factors, IGF receptors and IGF-binding proteins in primary cultures of prostate epithelial cells. J. Clin. Endocrinol. Metab.1991; 73: 401. Crossref, Medline, Google Scholar 16 : Insulin-like growth factor-binding protein-2 and -3 expression in benign human epithelium, prostate intraepithelial neoplasia, and adenocarcinoma of the prostate. J. Clin. Endocrinol. Metab.1996; 81: 411. Medline, Google Scholar 17 Plymate, S., Hwa, V., Thomasini, C., Maddison, L., Trasher, J., Swisshelm, K. and Rosenfeld, R.: Insulin-like growth factor binding protein-7 expression and regulation in the human prostate. Endocrine Society Annual Meeting, Minneapolis MN, pp. 351, 1997. Google Scholar 18 : Insulin-like growth factors and cancer. Br. J. Cancer1992; 65: 311. Crossref, Medline, Google Scholar 19 : Editorial: the possible autocrine/paracrine and endocrine roles of insulin-like growth factors of human tumors. Endocrinol.1990; 127: 1. Crossref, Medline, Google Scholar 20 : The insulin-like growth factor I receptor: a key to tumor growth?. Cancer Res.1995; 55: 249. Medline, Google Scholar 21 : Altered body and increased frequency of diverse malignancies in insulin-like growth factor-II transgenic mice. J. Biol. Chem.1994; 269: 13779. Crossref, Medline, Google Scholar 22 : A soluble insulin-like growth factor I receptor that induces apoptosis of tumor cells in vivo and inhibits tumorigenesis. Cancer Res.1995; 56: 4013. Google Scholar 23 : Insulin-like growth factors and cancers. Ann. Intern. Med.1995; 122: 54. Crossref, Medline, Google Scholar 24 : Insulin-like growth factor binding proteins in human breast cancer. Cancer Res.1992; 52: 5204. Medline, Google Scholar 25 : Expression of insulin-like growth factor binding proteins in human breast cancer correlates with estrogen receptor status. J. Cell. Biochem.1993; 52: 196. Crossref, Medline, Google Scholar 26 : Role for membrane and secreted insulin-like growth factor-binding protein-2 in the regulation of insulin-like growth factor action in lung tumors. Cancer Res.1993; 53: 4680. Medline, Google Scholar 27 : Suppressed expression of insulin-like growth factor binding protein-1 mRNA in the endometrium: a molecular mechanism associating endometrial cancer with its risk factors, Int. J. Cancer1994; 59: 307. Google Scholar 28 : Production of insulin-like growth factor binding proteins by human central nervous system tumors. Cancer Res.1991; 51: 3030. Medline, Google Scholar 29 : Elevated serum insulin-like growth factor binding protein-2 (IGFBP-2) and decreased IGFBP-3 in epithelial ovarian cancer: correlation with cancer antigen 125 and tumor associated trypsin inhibitor, J. Clin. Endocrinol. Metab.1997; 82: 2308. Google Scholar 30 : Immunohistochemical localization of insulin-like growth factor binding proteins 2 and 3 in prostate tissue: clinical correlations. J. Urol.1996; 155: 999. Link, Google Scholar 31 : Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. J. Endocrinol.1994; 142: 407. Crossref, Medline, Google Scholar 32 : IGF binding protein-3 secreted by the prostate adenocarcinoma cells (PC3): differential effect on PC-3 and normal prostate cell growth. Growth Reg.1993; 3: 180. Medline, Google Scholar 33 : Transforming growth factor-b-induced cell growth inhibition in human breast cancer cells is mediated through insulin-like growth factor-binding protein-3 action. J. Biol. Chem.1995; 270: 13589. Crossref, Medline, Google Scholar 34 : Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature1995; 377: 646. Crossref, Medline, Google Scholar 35 : Insulin-like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor beta 2-induced growth inhibition in human breast cancer cells. Cancer Res.1996; 56: 1545. Medline, Google Scholar 36 : 1α25-dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol (Ro24-5531) modulation of insulin-like growth factor-binding protein-3 and induction of differentiation and growth arrest in a human osteosarcoma cell line. J. Clin. Endocrinol. Metab.1996; 81: 93. Medline, Google Scholar 37 : Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. J. Clin Endocrinol Metab.1993; 77: 229. Medline, Google Scholar 38 : Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism. J. Biol. Chem.1997; 272: 12181. Crossref, Medline, Google Scholar 39 : Molecular genetics of recombinant insulin-like growth factor binding protein-3. In: Modern Concept of Insulin-Like Growth Factors. Edited by . New York: Elsevier1991: 715. Google Scholar 40 : SAS System for Mixed Models. Cary, NC: SAS Institute Inc1996. Google Scholar 41 : Insulin-like growth factor binding proteins. Recent Prog. Horm. Res.1990; 46: 99. Medline, Google Scholar 42 : The human insulin-like growth factor(IGF) binding protein-3 inhibits the growth of fibroblasts with a targeted disruption of the IGF-I receptor gene. Mol. Endocrinol.1995; 9: 361. Medline, Google Scholar 43 : Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J. Clin. Endocrinol. Metab.1992; 75: 1046. Medline, Google Scholar 44 : Matrix metalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures. J. Biol. Chem.1994; 269: 25742. Crossref, Medline, Google Scholar 45 : Endogenous cathepsin-D mediated hydrolysis of insulin-like growth factor-binding proteins in cultured human prostatic carcinoma cells. J. Clin. Endocrinol. Metab.1995; 80: 987. Medline, Google Scholar 46 : Type IV collagenase (Mr 72,000) expression in human prostate: benign and malignant tissue. Cancer Res.1993; 53: 878. Medline, Google Scholar 47 : Evaluation of cathepsin D and epidermal growth factor receptor in prostate carcinoma. Mod. Pathol.1994; 7: 930. Medline, Google Scholar 48 : Immunohistochemical analysis of cathepsin D in prostate carcinoma. Mod. Pathol.1994; 7: 747. Medline, Google Scholar From the Scott Department of Urology, Department of Medicine, Department of Pathology, Information Technology Program and Department of Cell Biology, Baylor College of Medicine and Veterans Affairs Medical Center, Houston, Texas© 1998 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited by Bostwick D and Cheng L (2020) Neoplasms of the Prostate Urologic Surgical Pathology, 10.1016/B978-0-323-54941-7.00009-8, (415-525.e42), . Harrison S, Lennon R, Holly J, Higgins J, Gardner M, Perks C, Gaunt T, Tan V, Borwick C, Emmet P, Jeffreys M, Northstone K, Rinaldi S, Thomas S, Turner S, Pease A, Vilenchick V, Martin R and Lewis S (2017) Does milk intake promote prostate cancer initiation or progression via effects on insulin-like growth factors (IGFs)? A systematic review and meta-analysisCancer Causes & Control, 10.1007/s10552-017-0883-1, VOL. 28, NO. 6, (497-528), Online publication date: 1-Jun-2017. Yen Y, Hsiao J, Jiang S, Chang J, Wang S, Shen Y, Chen C, Chang I, Chang J and Chen Y (2015) Insulin-like growth factor-independent insulin-like growth factor binding protein 3 promotes cell migration and lymph node metastasis of oral squamous cell carcinoma cells by requirement of integrin β1Oncotarget, 10.18632/oncotarget.5995, VOL. 6, NO. 39, (41837-41855), Online publication date: 8-Dec-2015. Sampson N, Zenzmaier C, Heitz M, Hermann M, Plas E, Schäfer G, Klocker H and Berger P (2013) Stromal Insulin-Like Growth Factor Binding Protein 3 (IGFBP3) Is Elevated in the Diseased Human Prostate and Promotes ex Vivo Fibroblast-to-Myofibroblast DifferentiationEndocrinology, 10.1210/en.2012-2259, VOL. 154, NO. 8, (2586-2599), Online publication date: 1-Aug-2013. Seligson D, Yu H, Tze S, Said J, Pantuck A, Cohen P and Lee K (2012) IGFBP-3 Nuclear Localization Predicts Human Prostate Cancer RecurrenceHormones and Cancer, 10.1007/s12672-012-0124-8, VOL. 4, NO. 1, (12-23), Online publication date: 1-Feb-2013. Micutkova L, Hermann M, Offterdinger M, Hess M, Matscheski A, Pircher H, Mück C, Ebner H, Laich A, Ferrando-May E, Zwerschke W, Huber L and Jansen-Dürr P (2011) Analysis of the cellular uptake and nuclear delivery of insulin-like growth factor binding protein-3 in human osteosarcoma cellsInternational Journal of Cancer, 10.1002/ijc.26149, VOL. 130, NO. 7, (1544-1557), Online publication date: 1-Apr-2012. Keku T, Sandler R, Simmons J, Galanko J, Woosley J, Proffitt M, Omofoye O, McDoom M and Lund P (2008) Local IGFBP-3 mRNA expression, apoptosis and risk of colorectal adenomasBMC Cancer, 10.1186/1471-2407-8-143, VOL. 8, NO. 1, Online publication date: 1-Dec-2008. Godoy G and Taneja S (2007) Contemporary clinical management of isolated high-grade prostatic intraepithelial neoplasiaProstate Cancer and Prostatic Diseases, 10.1038/sj.pcan.4501014, VOL. 11, NO. 1, (20-31), Online publication date: 1-Mar-2008. Bostwick D and Meiers I (2008) Neoplasms of the prostate Urologic Surgical Pathology, 10.1016/B978-0-323-01970-5.50011-7, (442-579), . Perry A, Loftus B, Moroose R, Lynch T, Hollywood D, Watson R, Woodson K and Lawler M (2007) In silico mining identifies IGFBP3 as a novel target of methylation in prostate cancerBritish Journal of Cancer, 10.1038/sj.bjc.6603767, VOL. 96, NO. 10, (1587-1594), Online publication date: 1-May-2007. Nelson E, Cambio A, Yang J, Ok J, Lara P and Evans C (2006) Clinical implications of neuroendocrine differentiation in prostate cancerProstate Cancer and Prostatic Diseases, 10.1038/sj.pcan.4500922, VOL. 10, NO. 1, (6-14), Online publication date: 1-Mar-2007. Zeng H and Botnen J (2007) Selenium is critical for cancer-signaling gene expression but not cell proliferation in human colon Caco-2 cellsBioFactors, 10.1002/biof.5520310302, VOL. 31, NO. 3-4, (155-164), . Lalani Z, Wong M, Brey E, Mikos A, Duke P, Miller M, Johnston C and Montufar-Solis D (2005) Spatial and Temporal Localization of FGF-2 and VEGF in Healing Tooth Extraction Sockets in a Rabbit ModelJournal of Oral and Maxillofacial Surgery, 10.1016/j.joms.2005.03.032, VOL. 63, NO. 10, (1500-1508), Online publication date: 1-Oct-2005. Lee K, Ma L, Yan X, Liu B, Zhang X and Cohen P (2005) Rapid Apoptosis Induction by IGFBP-3 Involves an Insulin-like Growth Factor-independent Nucleomitochondrial Translocation of RXRα/Nur77Journal of Biological Chemistry, 10.1074/jbc.M412757200, VOL. 280, NO. 17, (16942-16948), Online publication date: 1-Apr-2005. McCarty M (2016) Targeting Multiple Signaling Pathways as a Strategy for Managing Prostate Cancer: Multifocal Signal Modulation TherapyIntegrative Cancer Therapies, 10.1177/1534735404270757, VOL. 3, NO. 4, (349-380), Online publication date: 1-Dec-2004. Shimizu C, Hasegawa T, Tani Y, Takahashi F, Takeuchi M, Watanabe T, Ando M, Katsumata N and Fujiwara Y (2004) Expression of insulin-like growth factor 1 receptor in primary breast cancer: Immunohistochemical analysisHuman Pathology, 10.1016/j.humpath.2004.09.005, VOL. 35, NO. 12, (1537-1542), Online publication date: 1-Dec-2004. Miyata Y, Sakai H, Kanda S, Igawa T, Hayashi T and Kanetake H (2004) Expression of insulin-like growth factor binding protein-3 before and after neoadjuvant hormonal therapy in human prostate cancer tissues: correlation with histopathologic effects and biochemical recurrenceUrology, 10.1016/j.urology.2004.02.015, VOL. 63, NO. 6, (1184-1190), Online publication date: 1-Jun-2004. Mallipeddi R, Wessagowit V, South A, Robson A, Orchard G, Eady R and McGrath J (2004) Reduced Expression of Insulin-Like Growth Factor-Binding Protein-3 (IGFBP-3) in Squamous Cell Carcinoma Complicating Recessive Dystrophic Epidermolysis BullosaJournal of Investigative Dermatology, 10.1111/j.0022-202X.2004.22525.x, VOL. 122, NO. 5, (1302-1309), Online publication date: 1-May-2004. Bostwick D and Qian J (2004) High-grade prostatic intraepithelial neoplasiaModern Pathology, 10.1038/modpathol.3800053, VOL. 17, NO. 3, (360-379), Online publication date: 1-Mar-2004. Lalani Z, Wong M, Brey E, Mikos A and Duke P (2003) Spatial and temporal localization of transforming growth factor-β1, bone morphogenetic protein-2, and platelet-derived growth factor-A in healing tooth extraction sockets in a rabbit modelJournal of Oral and Maxillofacial Surgery, 10.1016/S0278-2391(03)00319-7, VOL. 61, NO. 9, (1061-1072), Online publication date: 1-Sep-2003. Miyata Y, Sakai H, Hayashi T and Kanetake H (2002) Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancerThe Prostate, 10.1002/pros.10175, VOL. 54, NO. 2, (125-132), Online publication date: 1-Feb-2003. Schwarze S, DePrimo S, Grabert L, Fu V, Brooks J and Jarrard D (2002) Novel Pathways Associated with Bypassing Cellular Senescence in Human Prostate Epithelial CellsJournal of Biological Chemistry, 10.1074/jbc.M200373200, VOL. 277, NO. 17, (14877-14883), Online publication date: 1-Apr-2002. Shariat S, Lamb D, Kattan M, Nguyen C, Kim J, Beck J, Wheeler T and Slawin K (2002) Association of Preoperative Plasma Levels of Insulin-Like Growth Factor I and Insulin-Like Growth Factor Binding Proteins-2 and -3 With Prostate Cancer Invasion, Progression, and MetastasisJournal of Clinical Oncology, 10.1200/JCO.2002.20.3.833, VOL. 20, NO. 3, (833-841), Online publication date: 1-Feb-2002. Winter D, Hanlon A, Raysor S, Watkins-Bruner D, Pinover W, Hanks G and Tricoli J (2001) Plasma levels of IGF-1, IGF-2, and IGFBP-3 in white and African-American men at increased risk of prostate cancerUrology, 10.1016/S0090-4295(01)01273-0, VOL. 58, NO. 4, (614-618), Online publication date: 1-Oct-2001. De Marzo A, Putzi M and Nelson W (2001) New concepts in the pathology of prostatic epithelial carcinogenesisUrology, 10.1016/S0090-4295(00)00952-3, VOL. 57, NO. 4, (103-114), Online publication date: 1-Apr-2001. Yu H, Nicar M, Shi R, Berkel H, Nam R, Trachtenberg J and Diamandis E (2001) Levels of insulin-like growth factor I (IGF-I) and IGF binding proteins 2 and 3 in serial postoperative serum samples and risk of prostate cancer recurrenceUrology, 10.1016/S0090-4295(00)01003-7, VOL. 57, NO. 3, (471-475), Online publication date: 1-Mar-2001. Hansson J and Abrahamsson P (2001) Neuroendocrine pathogenesis in adenocarcinoma of the prostateAnnals of Oncology, 10.1093/annonc/12.suppl_2.S145, VOL. 12, (S145-S152), . Nabhan C and Bergan R (2001) Chemoprevention in Prostate Cancer Cancer Chemoprevention, 10.1007/978-1-4615-1657-6_5, (103-136), . Cohen P, Clemmons D and Rosenfeld R (2000) Does the GH–IGF axis play a role in cancer pathogenesis?Growth Hormone & IGF Research, 10.1054/ghir.2000.0171, VOL. 10, NO. 6, (297-305), Online publication date: 1-Dec-2000. Mannhardt B, Weinzimer S, Wagner M, Fiedler M, Cohen P, Jansen-Dürr P and Zwerschke W (2000) Human Papillomavirus Type 16 E7 Oncoprotein Binds and Inactivates Growth-Inhibitory Insulin-Like Growth Factor Binding Protein 3Molecular and Cellular Biology, 10.1128/MCB.20.17.6483-6495.2000, VOL. 20, NO. 17, (6483-6495), Online publication date: 1-Sep-2000. Tricoli J, Winter D, Hanlon A, Raysor S, Watkins-Bruner D, Pinover W and Hanks G (1999) Racial differences in insulin-like growth factor binding protein-3 in men at increased risk of prostate cancerUrology, 10.1016/S0090-4295(99)00129-6, VOL. 54, NO. 1, (178-182), Online publication date: 1-Jul-1999. Volume 159Issue 6June 1998Page: 2220-2225 Advertisement Copyright & Permissions© 1998 by American Urological Association, Inc.MetricsAuthor Information ORI Z. HAMPEL More articles by this author MICHAEL W. KATTAN More articles by this author GUANG YANG More articles by this author S.JOE HAIDACHER More articles by this author GEORGES Y. SALEH More articles by this author TIMOTHY C. THOMPSON More articles by this author THOMAS M. WHEELER More articles by this author MARCO MARCELLI More articles by this author Expand All Advertisement PDF downloadLoading ...